Nektar Therapeutics sues Eli Lilly to undermine…

2017 company Nekta TherapyCollaborated with Eli Lilly and Company to develop a variety of drugs to alleviate autoimmune diseases.One of the drugs that appears to be doing well in preliminary tests for future commercialization is Rezpegardes Baigin.

The drug, being developed for the treatment of atopic dermatitis, achieved promising results in Phase 1b, with 10% compared to placebo on key efficacy measures including mean change in EASI, EASI-75, vIGA-AD scores and Itch NRS scale There is a dose-dependent improvement, ≥4 points.These improvements are in 36 additional weeks

After a 12-week treatment period.

“Durability of response may provide an opportunity for quarterly maintenance dosing regimens and better long-term disease control.”

Given these favorable results, “durability of response may present an opportunity for therapeutic optionsdose quarterly maintenance Better disease control in the long run. ” Jonathan Silverberg, Associate Professor of Dermatology, School of Medicine and Health Sciences George Washington University and Director of Clinical Research and Contact Dermatitis.

According to Reuters, despite this “victory”, the biopharmaceutical company Nektar Therapeutics be accused On Monday, Aug. 7, Eli Lilly accused the U.S. drugmaker of sabotaging The outlook for the drug

The two companies are collaborating on development.

The suit was filed in federal court in 2017 San Francisco Accused Lilly of breach of contract, negligent misrepresentation, unfair competition, etc. Irregularities. Seek compensatory and punitive damages, among other remedies.

“We are pleased to restore all rights to REZPEG”

Nektar recovered All rights There was more information about the drug earlier this year after the deal was terminated. “We are pleased to restore all rights to REZPEG”, commented howard robinChairman and CEO of Nektar.

Earlier this week, he said Eli Lilly had error report Data from two earlier studies testing rezpegaldesleukin for eczema and psoriasis clouded that information.According to Nektar, these new data show that within just 12 weeks of treatment with the drug at its highest dose, there were reduced severity

The incidence of eczema, also known as atopic dermatitis, was reduced by 83 percent, compared with a previously reported figure of 66 percent.